Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Innoviva, Inc. Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress July 31, 2024 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress May 08, 2024 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva to Participate in the BofA Securities Health Care Conference May 08, 2024 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress February 29, 2024 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 01, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023 October 11, 2023 From Innoviva, Inc. Via Business Wire Innoviva to Participate in the Cantor Global Healthcare Conference September 19, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults September 18, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Appoints Stephen Basso as Chief Financial Officer August 25, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress August 02, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference June 06, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use May 23, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases May 11, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress May 09, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Announces Retirement of Board Chairman April 28, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee April 17, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Stock Trading Halted Today April 17, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic March 13, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress February 28, 2023 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR) November 30, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress November 09, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference September 08, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Completes Acquisition of La Jolla Pharmaceutical August 22, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA LJPC Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress July 27, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment July 13, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Completes Acquisition of Entasis Therapeutics July 11, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc. July 08, 2022 From Innoviva, Inc. Via Business Wire Tickers ETTX INVA Innoviva to Acquire Entasis Therapeutics May 23, 2022 From Innoviva, Inc. Via Business Wire Tickers ETTX INVA Innoviva Reports First Quarter 2022 Financial Results April 27, 2022 From Innoviva, Inc. Via Business Wire Tickers INVA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.